fenbendazole has been researched along with cytochrome c-t in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dogra, N; Mukhopadhyay, T | 1 |
1 other study(ies) available for fenbendazole and cytochrome c-t
| Article | Year |
|---|---|
Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.
Topics: Activating Transcription Factor 3; Antinematodal Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cytochromes c; Cytotoxins; Endoplasmic Reticulum Chaperone BiP; Endoribonucleases; Fenbendazole; Heat-Shock Proteins; Humans; I-kappa B Proteins; Membrane Potentials; Neoplasms; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Transcription Factor CHOP; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitination | 2012 |